Drug Monograph

Drug/Drug Class:	**Actemra™ (tocilizumab) injection / DMARDS interleukin-6 receptor antagonist**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each 0.9 mLprefilled syringe of Actemra™ contains 162mg of tocilizumab.
Manufacturer:	Genentech, Inc., South Sa Francisco, CA 94080-4990
Indications:	Actemra (tocilizumab) is an interleukin-6 (IL-60) receptor antagonist indicated for treatment of Rheumatoid Arthritis (RA) in adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDS) and for patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis or systemic juvenile idiopathic arthritis.
Costs:	$715.00 per prefilled syringe of Actemra™. WholesaleAcquisitionCost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List and is a non-preferred agent.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-Preferred Agent ☐ Appropriate Indications ☐ No PA Required

Prepared By: Esther Shinkut, Pharm.D. candidate
Date: December 10, 2013